Since tumor cells failed to induce T cell responses, ICI (pembrolizumab (anti-PD-1), durvalumab (anti-PD-L1), and ipilimumab (anti-CTLA-4)) were added to the co-culture to improve anti-tumor reactions. The gene discussed is PDCD1; the disease is neoplasm.